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Three hundred and thirty-five patients with laboratory-confirmed Clostridium difficile infections
(CDIs) were studied for epidemiological features, clinical presentation and laboratory markers.
They were followed up for 1 year to determine recurrence and mortality. Four hundred and thirty-
two episodes were recorded. One year mortality was 41.8% of which CDI was listed on 20% of
the death certificates. One year recurrence rate was 22.9%. PCR ribotype 001 was the
commonest epidemiological type and ribotype 027 was not detected. High total leucocyte count
and low albumin were significantly associated with mortality, as was the absence of a GI-invasive
procedure in the 12 weeks preceding CDI diagnosis, probably due to patients being unfit for the
procedure. No association with acid suppressants, deletion in the tdcC anti-sigma factor or
vancomycin-resistant enterococcus/methicillin-resistant Staphylococcus aureus co-infection was
detected. One year mortality was higher in patients who developed recurrent infections
(P,0.001). Differences in ribotype were observed in 2.3%, 11.11%, 20% and 32.4% isolates
with time intervals between sampling of 0–20, 21–40, 41–60 and .60 days, respectively,
suggesting that the arbitrary cut-off of 28 days to call a repeat infection a reinfection may not be
correct in some cases.
INTRODUCTION
Clinical presentation of Clostridium difficile infections
(CDIs) can range from mild self-limiting diarrhoea to
severe, life-threatening infection, which can be rapidly
fatal. Between these two extremes lie disease syndromes,
including abdominal pain, fever and leucocytosis, pseudo-
membranous colitis, bowel perforation, sepsis and shock. A
characteristic feature of C. difficile is its propensity to cause
recurrent infections, which can increase the length of stay
and overall cost of hospitalization (Spencer, 1998). The
predisposing factors associated with recurrent CDI have
not yet been accurately determined, although a number of
studies have investigated the subject. Some of these
suffered from paucity of numbers and hence lacked the
power to detect significant differences between recurrent
and non-recurrent cases. This present study aimed to
evaluate the incidence, clinical features and molecular
characteristics of recurrent CDI in an area without ribotype
027.
Early identification of patients who are at high risk for
severe CDI may help clinicians to alter the modifiable
factors and hence improve outcomes. However, there is a
great deal of variation in the criteria used to study
adverse outcomes. Studies have used 30 day or 90 day
all-cause mortality, colonic surgery, pseudomembranous
colitis or various combinations of these as predictors of
adverse outcome. The most common end point used is
mortality up to 30 days from diagnosis (Bloomfield et al.,
2012).
Predictors of severity such as total leucocyte count, levels of
serum albumin, serum creatinine and CRP, age, co-
morbidities, length of hospital stay and immunosuppres-
sion have been studied. However, two recent systematic
reviews have concluded that the studies published so far
have several potential limitations like retrospective design,
poor sample size, single stage stool testing, and absence of
multivariable analyses to adjust for confounders (Abou
Chakra et al., 2012; Bloomfield et al., 2012).
The prevalence of epidemiological types of C. difficile varies
geographically but the recent increased incidence and
mortality has often been attributed to the suspected
hypervirulence of PCR ribotype 027. It is widely believed
that ribotype 027 can cause severe infections and higher
overall 30 day mortality than other ribotypes (Goorhuis
3Present address: Medical Microbiology, Kings College Hospital,
Denmark Hill, London, SE9 5RS, UK.
Abbreviations: CA, community-associated infection; CDI, Clostridium
difficile infection; CCI, Charlson co-morbidity index; GDH, glutamate
dehydrogenase; HA, hospital-associated infection; HCA, healthcare-
associated infection; HCF, health care facility.
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et al., 2011). However, in a Europe-wide, hospital-based
survey infection by ribotypes 018 and 056 was significantly
associated with complicated disease outcome (Bauer et al.,
2011).
This report describes a prospective study of mortality and
recurrence in an area where PCR ribotype 027 has been
absent. The incidence, clinical features and molecular
characteristics were studied with the aim to determine
whether the predisposing factors are different from other
studies performed in regions where PCR ribotype 027 has
been found.
METHODS
Patients. Patients whose stool samples were sent routinely to the
diagnostic microbiology laboratory of the Royal Infirmary of
Edinburgh from August 2010 to July 2011 and which tested positive
for C. difficile toxin by two-step glutamate dehydrogenase (GDH) and
toxin A/B ELISA (see later) were prospectively followed up for 1 year
after the first stool sample tested positive. Relevant ethical approval
was obtained for the study.
Data collection. Initial patient demographics, clinical features and
co-morbidity data were collected at the start of each episode of CDI,
at 10 days and at 1 year. For outpatients, the same data were collected
by telephone contact with the requesting doctor. Recovery, recur-
rence, treatment, and mortality were recorded. The Charlson co-
morbidity index (CCI) was calculated using a macro enabled Excel
tool available online (Hall et al., 2004). Haematological and
biochemical data (white cell count, creatinine, lactate) were obtained
from the local laboratory information system. Mortality data were
obtained from the NHS Lothian Public Health Department. Cause of
death was determined by reviewing the ICD codes on the death
certificates. ICD10 codes A04.7, A09, A41.4, A49.8 were included in
analysis (Anonymous, 2006).
Stool samples were tested using a two-step algorithm for C. difficile
toxin EIA (A and/or B) (Tox A/BII, Techlab) and GDH (C.DIFF
CHEK-60, Techlab). GDH-negative stools were excluded from the
study. The stools positive for both GDH and toxin EIA were cultured
on cefoxitin-cycloserine-egg yolk (CCEY) medium (Brazier, 1993).
All isolates were later subjected to toxin A and toxin B PCR (Persson
et al., 2011).
PCR ribotyping and detection of gene deletion. All DNA
templates were prepared by the Chelex DNA extraction method
(Stubbs et al., 1999). Previously published (Persson et al., 2011) toxin
gene primers (FAM labelled) were used in a multiplex format though
the cdtA was omitted, as it was the least informative. PET labelled
O’Neill primers were used for ribotyping (O’Neill et al., 1996). The
products of these PCRs were mixed in highly deionized (HiDi)
formamide (8 ml HiDi Liz 600 in 500 ml formamide buffer) and
analysed by capillary electrophoresis. The toxin multiplex and PCR
ribotyping protocols were initially run on the same thermocycling
protocol: initial denaturation at 95 uC for 5 min, 25 cycles of 95 uC for
60 s, 55 uC for 60 s and 72 uC for 90 s, final extension at 72 uC for
5 min. However, since the initial reactions for ribotyping were rather
weak, the cycle for ribotyping was later increased to 27 cycles. After
PCR, the products of the ribotyping and toxin gene multiplex were
mixed as follows. First dilution: 18 ml nuclease-free water and 10 ml
ribotyping PCR products and 2 ml toxin gene PCR product. This was
mixed well by pipetting. Final dilution, 1 ml of the diluted products
were mixed with 9 ml of HiDi formamide mix.
Capillary gel electrophoresis (ABI 3730) was used for PCR product
analysis and ribotypes were assigned by comparing with a set of
known strains on GeneMarker1 software version 1.95 (Softgenetics).
Known strains of ribotypes 001, 106 and 027 were included with each
run of ribotyping and toxin multiplex PCR for quality control. The
toxin gene images were compared against the PaLoc indicator panel
(kindly provided by Dr Derek Fairley).
Clinical case definitions. Clinical case definitions were adapted
from Society for Healthcare Epidemiology of America (SHEA) and
Health Protection Agency (HPA) guidelines (HPA, 2008; McDonald
et al., 2007). A case was defined as a patient with diarrhoea where the
stool takes the shape of the container (grade 5–7 as per Bristol stool
chart) or toxic megacolon with stool positive for C. difficile toxin A
and/or B without other known aetiology (McDonald et al., 2007). An
episode of CDI was defined as a case with the criteria above who
remains continuously symptomatic with a break of less than 48 h in
symptoms attributable to CDI. A repeat episode was defined as
another episode of CDI, which occurred after the duration of
treatment of the initial episode, with at least 48 h of an intervening
asymptomatic period.
Hospital-associated infection (HA-CDI) was defined as CDI that
developed after 48 h of admission into a health care facility (HCF),
community-associated infection (CA-CDI) was defined as CDI that
developed in a patient with no history of health care contact in the
12 weeks prior to diagnosis. Patients who were admitted in nursing
homes (without admission to a hospital in the past 12 weeks) and
those who had contact with a hospital in the past 4–12 weeks
(indeterminate category by SHEA definitions) were included in the
CA-CDI category.
Healthcare-associated infection (HCA-CDI) was defined as CDI
developing in a patient within 4 weeks of contact with a HCF but less
than 48 h after admission to a HCF. For the purpose of analyses, this
was included in the HA-CDI category.
Immunosuppression was defined as the presence of one or more of
the following conditions: acquired immunodeficiency syndrome
(AIDS), solid organ or haematopoietic stem cell transplant,
neutropenia, immunosuppressive drug or systemic corticosteroids
for .1 month, corticosteroid .10 mg or chemotherapy in last
2 months.
Major gastrointestinal (GI) procedure was defined as an invasive
procedure involving instrumentation, handling or surgical explora-
tion of the GI tract under anaesthesia. GI pathology was defined as
inflammatory, structural or neoplastic condition of the GI tract.
A patient was considered colonized with methicillin-resistant
Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus
(VRE) if electronic records stated that either of these had been isolated
from the patient any time in the past before the episode of CDI.
For statistical analyses of mortality, all patients who died with CDI
listed on their death certificates 1 year from diagnosis (n528) were
compared to those who were alive at 1 year or died due to
causes unrelated to the CDI (n5299). Thirty day all-cause mortality
(n563) was also compared to those who were alive at 30 days
(n5264).
For recurrent infections, patients who had a documented episode in
the past before the commencement of this study (n535) were
removed from analysis. In addition, to exclude those patients who die
before they get a chance to develop recurrence, all patients who died
within 30 days of development of CDI (n553) were also removed
from this analysis. Hence, a total of 247 patients were included in the
statistical analysis of this section (56 patients who developed more
than one episode and 191 patients who had only one documented
episode). Statistical analysis was performed using Minitab statistical
CDI-related mortality and recurrence in SE Scotland
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software version 15.1.0.0. Fisher’s exact test and the chi-square test
were used for categorical variables and the two-sample t-test for
numerical variables. Multivariate analyses were performed using
binary logistic regression analysis.
RESULTS AND DISCUSSION
Four hundred and twelve samples from 345 patients
(corresponding to 432 clinical episodes) were positive with
GDH and toxin ELISA combination testing. Of these, 10
samples were from patients under 2 years of age. Since the
significance of toxin positivity from this age to exclude
group is not clear, these were removed from further
analysis. Hence, 402 samples corresponding to 432 clinical
episodes were analysed.
The majority of samples were obtained from geriatric
subjects. The age distribution of the patients ranged from 2
to 97 years (mean age of 73 years). Of the 335 patients,
2.6% were under 18 years of age, 24.2% from 18 to 60
years and the remaining 73.1% were over 60 years of age.
This reflects the trend in previous years (Reddy et al.,
2010).
The CCI was available for 333 patients. Although the
unadjusted version was also recorded, the age-adjusted
version was used in the analyses. In this study, 19.2%
patients had a CCI score of 0. The use of acid-suppressing
medication was found in 51.3% patients and GI pathology
was found in 55.5% patients. A total of 19.1% patients
underwent a GI invasive procedure in the 12 weeks
preceding development of CDI and 57 patients in the
study were deemed to be immunosuppressed.
Results of statistical analyses are given in Tables 1–6.
Analysis of mortality
PCR ribotype. A recent study in the Netherlands followed
up 1350 cases of CDI of which 177 patients died within
30 days and 497 patients had died 1 year after diagnosis,
accounting for a mortality risk of 13.1% and 36.8%,
respectively (Hensgens et al., 2013). In the quoted study
20.8% of those with known ribotype 027, 15.8% with
known ribotype 001 and 14.8% with ribotype 078 died
within 30 days of diagnosis (PCR ribotypes were not
available for 49% of patients). Ribotype information was
available for only 25 patients who had CDI-related codes
on their death certificates, of which 24% were infected
with ribotype 078, 12% with ribotype 045 and 12% with
ribotype 001. Eight percent of all isolates were ribotype
027. Comparatively, in the present study, of the 335
patients, 63 died within 30 days of diagnosis (18.8%) and
140 (41.79%) were deceased within the 1 year of follow-
up. In addition, 21.7% with known PCR ribotype 001 and
21.4% with known ribotype 078 died within 30 days of
diagnosis. No isolates with PCR ribotype 027 were detected
in the study. Data were not available for eight patients. T
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Table 2. Bivariate analysis of categorical variables associated with death from CDI (as listed on the death certificate) within 1 year of the index episode, 30 day all-cause mortality
and 1 year CDI-related mortality
Variable Total (no.) CDI-specific mortality
within 1 y of index
episode (no.)
No CDI-specific
mortality within 1 y of
index episode (no.)
P-value* 30 day all-cause
mortality (no.)
Alive at
30 day (no.)
P-value*
Gender Male 118 10 108 0.966 22 96 0.830
Female 209 18 191 41 168
Immunosuppression Absent 273 23 250 0.793 57 216 0.096
Present 54 5 49 6 48
Place of acquisition CA 83 11 72 0.077 20 63 0.205
HA 244 17 227 43 201
Acid suppressants (PPI and H2
receptor antagonists)
Given 169 11 158 0.253 27 142 0.425
Not given 128 13 115 25 103
Underlying GI pathology Not known to be present 180 14 166 0.575 40 140 0.134
Present 147 14 133 23 124
Deletion detected in tcdC Absent 253 19 234 0.019 50 203 0.969
Present 50 9 41 10 40
Presence of cdtB No 265 21 244 0.037 51 214 0.521
Yes 38 7 31 9 29
Colonization with MRSA or VRE
prior to CDI
No 263 20 243 0.209 47 216 0.195
Yes 64 8 56 16 48
Invasive GI procedure in 12 weeks
prior to CDI
No 265 27 238 0.011 58 207 0.013
Yes 62 1 61 5 57
Antibiotics given 8 weeks prior to
CDID
No 33 4 29 0.329 7 26 0.694
Yes 272 21 251 50 222
Ribotype 078 27 5 22 0.881 6 21 0.741
Non-078 276 23 253 54 222
*Pearson’s chi-squared or Fisher’s exact test.
DIndividual antibiotics (penicillin V, piperacillin-tazobactam, amoxicillin, amoxicillin-clavulanic acid, flucloxacillin, clindamycin, macrolides, gentamicin, tetracycline, meropenem, cotrimoxazole,
nitrofurantoin, quinolones, 2nd and 3rd generation cephalosporins, glycopeptides, rifampicin, linezolid, metronidazole) were also compared but no statistically significant difference was found.
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Distribution of ribotypes in the patient group is given in
Fig. 1 and time to death stratified by information on the
death certificates is given in Fig. 2.
There have been suggestions that the ribotype of a C.
difficile isolate may determine its potential to cause severe
disease (Arvand et al., 2009; Baldan et al., 2010). However,
in keeping with other multivariate clinical studies (Walk
et al., 2012; Wilson et al., 2010), this study suggests that
mortality is not related to ribotype whereas there is a
positive correlation with total leucocyte count and serum
albumin (Tables 1 and 3). As is apparent from Fig. 1, there
is heterogeneity within this population and no particular
ribotype is over-represented. Ribotyping does however,
provide a method for classifying C. difficile isolates, which
is often required for epidemiological purposes and is a
starting point for comparative studies.
Differences in toxin genes tcdC and cdtB. The presence
of the binary toxin gene (cdtB), the major in-frame
deletions (18, 39 and 54 bp), the truncating 1 bp deletion
at position 117 and a C to T mutation at position 184 in
the toxin suppressor gene (tcdC: anti-sigma factor) was
compared and a significant difference was found between
the presence of a deleted tcdC (P50.019,) and presence of
the binary toxin gene (P50.037) between patients with and
without CDI-specific 1 year mortality as shown in Table 2.
However, this difference was not found in the multivariable
regression model (Table 3). It has been suggested
previously that these mutations are associated with
increased virulence (Carter et al., 2011; Knetsch et al.,
2011). However, doubts exist as to the significance of gene
deletions (Curry et al., 2007) and clinical studies have failed
to find a correlation between their presence and disease
outcome (Verdoorn et al., 2010; Goldenberg & French,
2011). The latter study did, however, suggest an association
between the presence of the binary toxin genes, increased
total leucocyte count and all-cause mortality at 30 days.
Age and gender. Age was significantly associated with
mortality in both groups in the bivariate analysis
(Table 1) but only with 30 day all-cause mortality in
the multivariable model. Past studies have reported
conflicting results. A study compared 82 patients who
survived and 46 patients who died within 30 days of CDI
and did not find a significant difference in age (.75 years)
or gender (Wilson et al., 2010). Conversely, an American
study compared the 30 day mortality due to CDI and
found age .80 years significantly associated with
mortality; however, there was no such association with
gender (Morrison et al., 2011).
Co-morbidities. The CCI was significantly greater in those
with 30 day mortality but not in the 1 year CDI-specific
mortality (Table 1). This association was not statistically
significant in the multivariable analyses (Tables 3 and 4). A
German study analysed factors likely to predict severe CDI
(defined as profuse diarrhoea associated with a heart rate
beats pm/systolic blood pressure mm Hg .1.5 at initial
diagnosis) and concluded that CCI was independently
associated with the risk, along with C-reactive protein
(Hardt et al., 2008). Other studies that have used the CCI
have also concluded that it is significantly different between
the two groups, although the end point used to define
Table 3. Binary regression model for multivariable analysis of factors associated with CDI-related mortality within 1 year of index
episode
Variable P-value Odds ratio 95% CI
Lower limit Upper limit
Age 0.147 1.03 0.99 1.06
Presence of cdtB 0.5 1.99 0.27 14.59
Presence tcdC deletion 0.483 0.51 0.08 3.31
GI procedure within 12 weeks preceding index episode 0.026 0.06 0.01 0.72
Leucocyte count (cells6109 l21) 0.016 1.07 1.01 1.13
Serum albumin level at onset (g l21) 0.014 0.90 0.82 0.98
Table 4. Binary regression model for multivariable analysis of factors associated with 30 day all-cause mortality
Variable P-value Odds ratio 95% CI
Lower limit Upper limit
Age (y) 0.014 1.03 1.00 1.06
GI procedure within 12 weeks preceding index episode 0.020 0.25 0.08 0.80
Leucocyte count (cells6109 l21) 0.004 1.06 1.02 1.11
Serum albumin level at onset (g l21) 0.086 0.95 0.89 1.01
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severity and the cut-off score used vary between the studies
(Das et al., 2010; Labbe´ et al., 2008; Cadena et al., 2010).
The CCI score includes various co-morbidities and is
generally used as an indicator to assess the risk of dying
within 1 year. Since it includes various chronic conditions,
it is useful as a combination indicator negating the need to
assess each co-morbidity independently. However, since it
involves the analysis of 19 different parameters its practical
application as a routine marker of severity is difficult.
Table 5. Bivariate analysis of continuous variables compared between the patients with recurrent and non-recurrent CDI
Variable Recurrent CDI Non-recurrent CDI P-value*
n Mean SD SE mean n Mean SD SE mean
Age (y) 56 69.9 18.8 2.5 191 62.8 22.5 1.6 0.020
CCI (age adjusted) 56 4.86 2.77 0.37 189 4.11 3.2 0.23 0.089
Antibiotics given 8 weeks
preceding onset (no.)
50 2.18 1.44 0.20 175 1.79 1.29 0.098 0.092
Leucocyte count
(cells6109 l21)
49 13.8 7.47 1.1 155 12.21 7.33 0.59 0.198
Serum albumin level at onset
(g l21)
35 28.11 5.7 0.97 123 30.49 7.13 0.64 0.045
*Two-sample t-test without assuming equal variances.
Table 6. Bivariate analysis of categorical patients between patients who developed recurrent and non-recurrent CDI
Variable Recurrent
CDI (no.)
Non- recurrent
CDI (no.)
Total (no.) P-value*
Gender Male 19 67 86 1.000
Female 37 124 161
Immunosuppression Present 7 37 4 0.321
Absent 49 154 203
Place of acquisition CA 18 42 60 0.155
HA 38 149 187
Antacids (PPI and H2 receptor antagonists) Present 31 94 125 0.334
Absent 19 82 101
Underlying GI pathology Present 28 80 108 0.288
Absent 28 111 139
Deletion detected in tcdC Present 6 32 4 0.295
Absent 48 144 192
Colonization with MRSA or VRE prior to CDI Present 12 39 59 0.853
Absent 44 151 195
GI-invasive procedure in 12 weeks prior to CDI Performed 9 47 56 0.207
Not performed 47 144 191
Use of tazocin in 8 weeks preceding illness Yes 20 54 74 0.234
No 30 122 152
Severity of first episode Non-severe 28 109 137 0.281
Severe 27 75 102
Antibiotics given 8 weeks prior to CDI Yes 49 156 205 0.078
No 2 24 26
Presence of cdtB Present 6 23 29 0.818
Absent 48 153 201
Ribotype 001 12 17 29 0.024
078 2 18 20
1 year mortality from CDI Yes 9 1 10 0.000
No 46 183 229
*Fisher’s exact test.
CDI-related mortality and recurrence in SE Scotland
http://jmm.sgmjournals.org 1473
Antibiotics. Antibiotics disrupt the normal flora of the gut
allowing C. difficile to proliferate and cause CDI. In the
present study administration of antibiotics in the 8 weeks
preceding CDI onset was compared but there was no
statistical difference found. Each individual antibiotic was
also analysed separately but no statistically significant
difference was found (Table 2). The use of antibiotics has
been studied in the past but an American study (Morrison
et al., 2011) also did not find a statistical correlation
between their use and 30 day mortality.
Total leucocyte count and serum albumin. Total
leucocyte count was found to be statistically significant in
both bivariate and multivariate analyses (Tables 1, 3 and 4)
though serum albumin was not significant in the
multivariable model of 30 day all-cause mortality.
Previous studies have examined the association of these
markers using cut-off values varying from .15 cells 6
109 l21 to .30 cells 6 109 l21 for total leucocyte count
and from ,20 g l21 to ,30 g l21 for albumin, some also
having used mean values (Dharmarajan et al., 2000; Gujja
& Friedenberg, 2009; Andrews et al., 2003; Pe´pin et al.,
2007). Although the criteria for outcome varied between
the studies, a recent meta-analysis found that both these
parameters were useful markers of severity to determine
outcome (Bloomfield et al., 2012).
Invasive GI procedures and underlying GI pathology.
There was a negative correlation of the performance of an
invasive GI procedure with death in both analyses. The
reason for this paradoxical phenomenon is not clear but
may be due to patients being generally more unfit to
undergo a GI procedure and hence more likely to die than
those who are considered fit to undergo GI invasion. The
presence of an underlying GI pathology was not different
between the groups studied.
Immunosuppression. The definition of immunosup-
pression is not standardized and hence it is difficult to
compare directly the results of this study with those of
others. This may also be a reason why there is heterogeneity
in the reported significance of immunosuppression as a
predictor of mortality. However, a large study comparing
three groups of patients with CDI (without steroids), CDI
with steroids and a non-CDI control arm suggested that
the use of any glucocorticoid resulted in an increased
mortality with a hazard ratio of 2.1±0.19 (P,0.001)
comparing all patients who had CDI. Mortality at 30 days
was higher in the CDI with steroids group as compared to
those without steroids (19.3 vs 9.6%) (Das et al., 2010).
Hence, it is likely that immunosuppression is related to
adverse outcome in CDI. This was however, not detected in
the present study.
Hospital-associated acquisition and prior colonization
with MRSA/VRE. These factors were not found to be
significantly associated in any of the above statistical
comparisons of mortality. Since the definition of hospital
acquisition has only recently been standardized, the studies
that have examined this variable have used a variety of
definitions.
Antacids (including proton-pump inhibitors). A statisti-
cally significant correlation was not found in the use of acid
suppressant medication and the development of severe
CDI in any of the above analyses.
Analysis of recurrent infections
In the present study, 19.4% of patients experienced more
than one episode (recurrence or relapse) in the 1 year
follow-up period. After removal of patients who had a
documented episode in the past (n535) and all patients
who died within 30 days of development of CDI (n553)
the recurrence rate was 22.9%. The incidence of recurrent
CDI has been reported to range from 15 to 35% of cases
(Fekety et al., 1997; Barbut et al., 2000).
Total leucocyte count and serum albumin. The present
study did not find an association between total leucocyte
count and recurrence; however, the albumin levels
appeared to be statistically significant (Table 5). Choi et
al. (2011) reported that white blood cell count, serum
albumin and C-reactive protein at diagnosis were not
significantly different between the recurrent and non-
recurrent groups. Eyre et al. (2012) studied 12 biomarkers
in their study group but only higher C-reactive protein
level and higher neutrophil count at first CDI
independently appeared to increase the recurrence risk.
Patients with recurrences were also more likely to die
within 1 year from the first episode as compared to those
without recurrent disease. Interestingly, in our study,
ribotype 001 was associated with more recurrent disease
than ribotype 078 (Table 6).
Association with antibiotics. CCI, administration of
antibiotics 8 weeks prior to the first episode and the total
number of different antibiotics given prior to CDI were
also trending towards a statistically significant value (P-
values of 0.089, 0.078 and 0.092, respectively).
In the same study mentioned previously (Choi et al., 2011),
patients who received more than three antibiotics were
more common in the recurrent group as compared to the
non-recurrent group, but this association was not found
after adjusting for confounders.
Gastric acid-suppressing agents. No statistically signi-
ficant difference (P50.334) was found between the use of
acid-suppressing agents (proton-pump inhibitors, and H2-
receptor antagonists) in the two groups analysed in the
present study. This reflects the findings of a previous study
examining recurrent disease and the use of these agents
(Choi et al., 2011). However, a study by Tal et al. (2002)
did find the use of H2 receptor antagonists to be a
S. K. Taori, A. Wroe and I. R. Poxton
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statistically significant predictor of recurrent CDI
(P¡0.02).
Immunosuppression. Although previous studies have
reported recurrent CDI associated with allogeneic stem
cell transplant (Chang et al., 2012) and GI graft versus host
disease (Alonso et al., 2012), the lower power in these
studies did not allow this factor to be studied in detail. A
higher-powered recent analysis did not find a statistically
significant correlation between dialysis or chemotherapy
and development of recurrent CDI (Eyre et al., 2012). In
keeping with this finding, the present study did not find a
correlation between immunosuppression and risk of CDI.
Other hospital-associated pathogens. A retrospective
cohort of 84 patients with CDI found enteric colonization
with VRE to be statistically correlated with the risk of
developing recurrent CDI (Choi et al., 2011). The reason
for this phenomenon is unclear though since VRE and C.
difficile are both recognized hospital-associated pathogens,
the co-infection could be due to shared risk factors rather
than a direct causative role. In the present study, the effect
of colonization with either VRE or MRSA was evaluated
(Table 6) but not found to be statistically significant. Eyre
et al. (2012) also studied the effect of prior MRSA
colonization and it appeared to be a possible factor in
the univariable analysis but they did not find it a
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statistically significant predictor on the multivariable
model.
Molecular analysis of recurrences
Differences in ribotype were observed in 2.3%, 11.11%,
20% and 32.4% of isolates with time intervals between
sampling of 0–20, 21–40, 41–60 and .60 days, respectively
(Fig. 3). This chart demonstrates a steady rise in the
proportion of isolates, which were different as compared to
the previous ribotype isolated from the same patient when
plotted against time. In the column 0–20 days, there was
one isolate at 16 days, in column 21–40 days, there were
three isolates at 23, 26 and 27 days.
This result suggests that the arbitrary cut-off of 28 days to
call a repeat infection a reinfection may be correct in the
majority of cases where the ribotype is different; however,
there are some cases (four in this study) where there is a
different ribotype isolated even before 28 days. This must
be kept in mind if a patient presents again with symptoms
after a period of recrudescence or if the nature of illness
changes from mild to severe, since this may be due to a
reinfection.
On the other hand, there are a number of isolates obtained
from the same patient even after 28 days where the
ribotype is the same as the previous isolate. This suggests
that even though a patient may present with a fresh set of
symptoms after 28 days it may be the same episode and
hospitals should not be considered liable for this new
infection if it is the same strain being carried by the patient.
If this new set of symptoms occurs in hospital, it is likely to
be due to antibiotic usage or due to other predisposing
factors, which may or may not be modifiable.
An earlier study (Wilcox et al., 1998) defined recurrence of
C. difficile diarrhoea as the resumption of symptoms, after
cessation for at least 3 days, with laboratory-confirmed
cytotoxin-positive faeces. They analysed C. difficile isolates
by RAPD analysis and found that 56% of clinical
recurrences of infection are in fact due to reinfection as
opposed to relapse.
In a study comprising C. difficile isolates from 102 patients
with repeat episodes of CDI (Kamboj et al., 2011), it was
found that in those patients who had a second episode
within 2–4 weeks of the original episode 90% had the same
ribotype, those who had a second episode 4–8 weeks apart
had the same ribotype in 86.5% of cases and episodes
separated by .8 weeks had the same ribotype in 65% of
cases. Results from our study are roughly comparable with
this recent study.
Another study that compared strains by serotyping from
repeat episodes of CDI from patients found two different
serogroups in 21.5% of patients and the same serogroup in
78.5% of cases. PCR ribotyping was used to discriminate
the latter group and showed a different pattern in 65.7% of
cases. Their results suggest that 45 of 93 (48.4%) clinical
recurrences were in fact due to reinfections with a different
strain. Delay of relapse and reinfection had a median of 28
and 38 days, respectively (Barbut et al., 2000).
This study adds to the existing knowledge of these complica-
tions of CDI. Characteristics of CDI-related mortality and
recurrence seen in this region of Scotland have been
documented and the effects of potential predisposing factors
analysed. Compared to studies in which ribotype 027 has been
reported in an endemic situation without major outbreaks,
there do not appear to be any noteworthy differences.
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